RxDoctor Payments Data

Frank Mazzola, MD

Clinical Cardiac Electrophysiology · Harlingen, TXNPI 1558323915

Payments from drug & device makers

$76,280in general payments, 2019–2025

Across 403 payments — averaging $189.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$62K
  • Medical Device Business Services, Inc.$6K
  • Biosense Webster, Inc.$4K
  • Medtronic$2K
  • Abbott$1K
  • Impulse Dynamics (USA) Inc.$139
  • plus $367 from 7 others

What the payments were for

  • Consulting fees$8751%
  • Speaking & faculty fees$22,20029%
  • Travel & lodging$38,54251%
  • Food & beverage$14,65019%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,280 in reported general payments places this provider in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$296,114
Medicare patients
483
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$236,416
MultaqDronedarone Hcl213$214,646
Droxidopa32$108,006
XareltoRivaroxaban85$95,809
Propafenone Hcl ErPropafenone Hcl174$27,950
Pindolol110$9,069
Diltiazem 12hr ErDiltiazem Hcl18$3,876
Midodrine Hcl16$3,538
Metoprolol Succinate219$3,268
Dabigatran EtexilateDabigatran Etexilate Mesylate15$2,110
Flecainide Acetate76$2,013
Verapamil ErVerapamil Hcl99$1,894
Amiodarone Hcl160$1,846
Diltiazem 24hr Er (La)Diltiazem Hcl40$1,638
Dilt-XrDiltiazem Hcl58$1,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$95,80985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →